hVIVO’s (HVO) Buy Rating Reaffirmed at Shore Capital

Shore Capital reaffirmed their buy rating on shares of hVIVO (LON:HVO) in a report released on Thursday morning, MarketBeat Ratings reports. Shore Capital currently has a GBX 25 target price on the stock.

Separately, Peel Hunt reiterated an “add” rating and issued a GBX 10 price objective on shares of hVIVO in a report on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of GBX 17.50.

hVIVO Trading Down 2.4%

LON:HVO opened at GBX 6.05 on Thursday. The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. hVIVO has a 12 month low of GBX 4.31 and a 12 month high of GBX 20. The company has a 50-day moving average price of GBX 5.98 and a 200-day moving average price of GBX 7.69. The stock has a market cap of £41.58 million, a price-to-earnings ratio of 7.86 and a beta of 0.97.

Insider Activity

In related news, insider Yamin Mo’ Khan bought 3,310,405 shares of the business’s stock in a transaction on Monday, December 15th. The stock was acquired at an average price of GBX 6 per share, with a total value of £198,624.30. Also, insider Stephen Pinkerton acquired 520,000 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The stock was purchased at an average cost of GBX 6 per share, with a total value of £31,200. 4.43% of the stock is currently owned by company insiders.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.